Avacincaptad Pegol Sodium

CHEMBL4297889 Phase 4 Aprobado Unknown
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A pegylated RNA aptamer that binds and inhibits complement component C5, blocking a branch of the complement system that drives the destruction of retinal cells in geographic atrophy. It is administered by intravitreal injection.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A pegylated RNA aptamer that binds and inhibits complement component C5, blocking a branch of the complement system that drives the destruction of retinal cells in geographic atrophy. It is administered by intravitreal injection.

Yes, Avacincaptad Pegol Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297889. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.